Pharmaceuticals&Medical Products

Dec. 18, 2007: Announcement of the Launch of the Pulmonary Arterial Hypertension Agent Careload® LA Tablets 60¯g in Japan
Oct. 22, 2007: Announcement of the Acquisition of Marketing Approval for the Pulmonary Arterial Hypertension Agent Careload® LA Tablets 60µg in Japan
-- The World First Oral Prostacyclin (PGI2) Derivative Prolonged Release --
Jun. 29, 2007: Torii, Toray starts to Co-Promote Hemoperfusion absorption column Toraymyxin* for removing endotoxin
Nov. 28, 2006: New Drug Application of Antipruritic Agent “TRK-820” for the Treatment of Severe Pruritus in Hemodialysis Patients in Japan
Sep. 4, 2006: Toray, JT, Torii Agree to Co-Develop and Market TRK-820 Antipruritus Drug for Hepatic Disease Patients in Japan
Dec. 5, 2005: Toray, DNA Chip Research to Jointly Develop New DNA Microarrays
-- Aiming for De Facto Standard With Commercialization of High Performance DNA Chips--
Oct. 31, 2005: Maruho and Toray Partner on Phase III Therapeutic for Dialysis Patients in Europe
Apr. 07, 2005: Toray and Takeda to Jointly Develop and Market an Investigational Compound for Frequent Urination/Urinary Incontinence
Mar. 31, 2005: Maruho, Toray Agree to Co-Develop and Market New Atopic Dermatitis Drug in Japan
Mar. 16, 2005: Toray, Japan Tobacco, Torii Pharmaceutical Agree to Co-Develop and Market
New Antipruritus Drug in Hemodialysis Patients in Japan
Sep. 17, 2004: Achieving Ultra-Sensitivity and High Reproducibility in Development of Next Generation DNA Microarray Base Aiming for Innovations in Drug and Healthcare Field By Integrating Nano- and Bio-Technologies --
May 14,2003: Toray and Nippon Shinyaku to Jointly Develop Oral Controlled-Release Painkiller
Jan. 29,2003: Toray and Fujisawa Agree to Co-development and Exclusive License of Its New Antipruritus Drug in Europe